Jan 15, 2026 · 1h 29m · allin
Supercharging a New FDA: Marty Makary on Science, Power & Patients
0:00 / 0:00
▶ Watch on YouTube →
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In an in-depth interview at the JP Morgan Healthcare Conference, FDA Commissioner Dr. Marty Makary outlines comprehensive regulatory reforms aimed at accelerating medical innovation, lowering drug prices, and restoring public trust in federal health policy. He details structural shifts including streamlined clinical trials, AI integration, food pyramid overhauls, and root-cause research into childhood chronic diseases.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. How this is scored →
The hosts as informed peer 2.4 Guest teaching 3.7 Guest disagreement 1.4 The hosts pushing back 0.8
speaking balance: gold is the hosts, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 2:10 Forceful critique of COVID public health policies
Dr. Makary strongly rejects past public health consensus, calling natural immunity denial one of the most scientifically dishonest statements made by scientists and criticizing toddler mask mandates.
Hardest push from the hosts ▶ 1:07:43 Host defends pharma advertising using CEO argumentThe host directly counters the premise that direct-to-consumer pharma ads should be restricted, quoting a pharmaceutical CEO on physician education deficits.
Biggest teaching moment ▶ 34:00 Reframing dietary guidance and childhood metabolic diseaseDr. Makary reframes the host's question on dietary guidelines by delivering detailed epidemiological observations on how low-fat dogma drove refined carb consumption and high prediabetes rates in children.
The host holds their own ▶ 7:50 Host presents detailed biotech competition metricsThe host demonstrates strong domain knowledge by citing specific figures from the Congressional National Security Commission report regarding Chinese licensing deals, valuation figures, and paper output rates.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | The hosts as informed peer | Guest teaching | Guest disagreement | The hosts pushing back | Why |
|---|---|---|---|---|---|---|
| Dr. Makary's Journey to FDA Commissioner and COVID Retrospective | 1 | 3 | 2 | 0 | The host asks open-ended introductory questions about how Dr. Makary became FDA commissioner and his public stances during COVID. Dr. Makary details his academic background, hospital price transparency work, and critiques legacy COVID public health measures. | |
| Overcoming Institutional Conflict and Reforming FDA Operations | 2 | 4 | 2 | 2 | The host presses Dr. Makary on criticisms from former employees regarding agency turmoil and staff reductions. Dr. Makary defends the restructuring, noting that scientific reviewers were retained while redundant IT and HR roles were consolidated. | |
| US vs. China Biotech Competition and Trial Streamlining | 4 | 3 | 1 | 1 | The host opens with detailed statistics from a commission report comparing US and Chinese biotech deal flow and publication outputs. Dr. Makary agrees with the competitive threat and outlines reforms to centralized IRBs and hospital contracting. | |
| Redefining Approval Pathways and Eliminating Animal Testing | 2 | 5 | 2 | 0 | The host asks for an overview of trial phases to highlight regulatory burdens. Dr. Makary explains eliminating requirements like chimpanzee testing for monoclonal antibodies and dropping the default requirement from two pivotal trials to one. | |
| Accelerating Approvals with AI and Real-Time Continuous Trials | 3 | 4 | 1 | 0 | The host asks whether digitized health data and AI can merge clinical trial phases into computationally assisted approvals. Dr. Makary expands on this vision, announcing new FDA policies allowing Bayesian statistics for continuous trial monitoring. | |
| Risk vs. Benefit Perception and Right to Try Expansion | 4 | 3 | 1 | 1 | The host uses a detailed Waymo autonomous driving analogy to explain public misperceptions of absolute risk versus drug speed benefits. Dr. Makary validates the framing and discusses expanding Right to Try flexibilities. | |
| Cell and Gene Therapy Manufacturing Flexibilities and CAR-T Innovations | 3 | 4 | 2 | 0 | The host asks technical questions about whether modified batch requirements affect GMP facilities and CAR-T applications in autoimmune conditions. Dr. Makary explains tailored manufacturing standards and notes halting Biden-era T-cell editing shipments to China. | |
| Uncovering FDA Bureaucracy and Structural Restructuring | 1 | 2 | 1 | 0 | The host asks Dr. Makary about unexpected administrative discoveries upon taking office. Dr. Makary shares anecdotes about physical paper transfers between isolated agency centers and an employee assigned solely to fax ink maintenance. | |
| Overhauling the Food Pyramid and Targeting Childhood Chronic Disease | 2 | 5 | 2 | 1 | The host prompts a discussion on the revised food pyramid guidance and historical nutrition corruption. Dr. Makary critiques the legacy focus on saturated fats, arguing refined carbs created widespread childhood metabolic disease. | |
| Food Industry Incentives, Real Food Guidance, and GLP-1 Agonists | 2 | 4 | 1 | 2 | The host playfully critiques the lack of vegetarian proteins atop the new pyramid diagram before asking about food industry incentives and GLP-1 agonists. Dr. Makary elaborates on systemic insulin resistance and broader therapeutic effects of GLP-1 drugs. | |
| NIH Research Funding Reallocation and Root-Cause Science | 2 | 4 | 2 | 2 | The host challenges Dr. Makary on claims that the Trump administration is defunding scientific research. Dr. Makary clarifies that overall NIH funding was maintained while shifting resources away from DEI grants toward root-cause health research. | |
| Reforming Childhood Vaccine Schedules and Restoring Public Trust | 3 | 4 | 2 | 1 | The host shares his personal decision to decline the birth-day Hepatitis B vaccine for his newborn, prompting Dr. Makary to explain narrowing the recommended childhood vaccine schedule to 38 core doses to rebuild public trust. | |
| Lowering Drug Prices: Most Favored Nation Pricing, Biosimilars, and OTC Approvals | 2 | 4 | 1 | 1 | The host raises the high cost of US prescription drugs compared to international markets. Dr. Makary outlines Most Favored Nation pricing, fast-tracking biosimilars, and pushing over-the-counter approvals to bypass PBM markups. | |
| Regulating Direct-to-Consumer Pharma Ads and DTC Enforcement | 3 | 3 | 2 | 2 | The host pushes back against TV ad bans by citing a pharma CEO's argument that ads inform patients when physicians fail to read medical journals. Dr. Makary counters by citing 1,500 enforcement letters sent to stop misleading drug campaigns. | |
| AI Diagnostics, Health Wearables, and FDA Regulatory Frameworks | 2 | 3 | 1 | 0 | The host asks how the FDA plans to handle AI diagnostic tools and health wearables without over-regulating innovation. Dr. Makary explains establishing a consumer health lane while requiring validation only for items claiming medical grade status. | |
| Alternative Proteins, GRAS Deregulation, and Dietary Protein Needs | 3 | 3 | 1 | 1 | The host asks about alternative protein regulation, rancher lobbying, and GRAS self-declarations. Dr. Makary discusses closing GRAS chemical loopholes while creating registration pathways for cellular foods. | |
| Investigating Autism Causes, Leucovorin Treatments, and Gut Microbiome | 2 | 5 | 1 | 1 | The host asks about rising autism rates and recent discussions on Leucovorin treatments. Dr. Makary details biological hypotheses, including autoimmune folate-receptor blocking and microbiome disruption from childhood antibiotics. | |
| Chronic Disease, Systemic Inflammation, and Reevaluating Nutritional Dogma | 2 | 4 | 1 | 0 | The host asks for Dr. Makary's outlook on exciting medical frontiers. Dr. Makary re-evaluates chronic disease causes and highlights FDA fast-track vouchers issued for myeloma gene therapies and congenital deafness treatments. |
Statements from this episode (43)
FDA Chief Makary: Ignoring COVID natural immunity was 'scientifically dishonest'
“Ignoring natural immunity, one of the most scientifically dishonest things a scientist could possibly say about the virus and the immunity.”
FDA Commissioner Makary announces 42 major reforms in first 10 months
“We have announced 42 major reforms in my 10 months in office at the FDA.”
Makary: FDA now makes all drug rejection letters public
“Our rejection letter is public, so that if the FDA does not approve a drug, the public deserves to know why.”
FDA removes nine artificial petroleum-based food dyes from U.S. market
“Within weeks of coming into office, we took action to remove all nine artificial petroleum-based dyes.”
Makary: No FDA scientific reviewers were laid off during administrative cuts
“No scientific reviewer was laid off, but there were significant consolidations in HR, procurement, IT, and the duplicative services that were out there.”
FDA hiring 1,050 new scientists to expand accelerated drug approval pathways
“We are actually hiring 1050 new scientists because we have very ambitious goals on our new pathways, accelerated type pathways, and so we're building up capacity to have a whole new line of pathways so that we can deliver faster for the American people.”
Makary: FDA will use AI to cut application reviews to one day
“It took, and you know, some often still takes, 60 days just for the FDA to tell you that your application is complete. We're going to get that down to one day. We're going to use AI.”
Makary: FDA reduces default drug approval requirement to one pivotal trial
“We announced just last month that we are going to go from a baseline default requirement of two pivotal trials for a drug to one pivotal trial for a drug.”
Makary: 90% of drugs passing animal testing fail in human trials
“90% of drugs that pass animal studies do not pass safety and efficacy in humans.”
Makary: FDA granted 18 vouchers for rapid-approval pilot program
“We have, I think, 18 products that have vouchers for this new pilot program.”
FDA to allow Bayesian statistics in clinical trial evaluations
“Which we announced this week. We are now going to allow Bayesian statistics to be used.”
Makary says he has approved 100% of Right to Try requests
“And I have signed 100% of Right to Try requests that come across my desk.”
FDA eliminates select regulatory requirements for cell and gene therapies
“And we announced just this week that we are getting rid of the, some of the regulatory requirements for cell and gene therapy.”
Makary: FDA is customizing drug manufacturing requirements to specific patient populations
“The announcement that we made on Sunday was that we're going to customize the manufacturing requirements to the drug and the population being treated.”
Makary: FDA created a plausible mechanism pathway for bespoke gene therapies
“These bespoke therapies, we created essentially a novel pathway for them. Dr. Vinay Prasad described it in the New England Journal of Medicine. It's called the plausible mechanism pathway, and it's basically combining gold standard science with common sense.”
Makary: FDA halted Biden-era policy allowing CAR-T cell editing in China
“We did find that there was in the Biden administration approval to have the cells of Americans for CAR T therapy shipped to China where the Chinese did the gene editing and then shipped back to the United States. To infuse in Americans. When I found out about …”
Makary: 38% of American children have prediabetes or diabetes
“38% of kids have prediabetes or diabetes.”
Makary: Refined carbs comprise 60% to 70% of American children's calories
“60 to 70% of the calories of a child in America today are refined carbohydrates.”
Makary: 16-year peanut avoidance rule sparked modern peanut allergy epidemic
“Young kids should avoid peanut butter until they turn three. We got that wrong for 16 years. Tragically wrong. Igniting the modern day peanut allergy epidemic because peanut butter exposure in infancy reduces, there's something called immune tolerance, right? …”
Makary: Insulin resistance is at the root of almost every chronic disease
“And it is at the root of almost every chronic disease, insulin resistance, general body inflammation,”
Makary: 40% of American children have a chronic disease
“Well, first of all, we have failed with our food system. Look at the fact that 40% of American kids have a chronic disease.”
Makary: GLP-1 drugs reduce insulin resistance and systemic inflammation
“GLP-I's are mimicking a natural hormone in the body. And so when you get a supplementation of that, it's doing the job of increasing satiety, slowing down GI motility, and it has a profound impact on a number of conditions because you are also reducing insulin…”
Makary: The Trump administration has not cut any NIH funding
“In the Trump administration, we have not cut one dollar of NIH funding.”
Makary: One in six girls today will develop an autoimmune disease
“Where's the research on why one in six girls today will develop an autoimmune disease?”
Makary claims 14% of all NIH grants went to DEI research
“14% of any NIH grants went to DEI research.”
Makary: U.S. childhood vaccine schedule was an international outlier at 72 doses
“The United States vaccine schedule was an international outlier with 72 doses recommended between the ages of zero and 18.”
Makary: Federal health officials released reduced core vaccine schedule of 38 doses
“So we gave them a list that constitutes about 38 doses from age zero to 18.”
Makary: 40% of eligible US women do not get mammograms
“40% of women who are candidates for a mammogram are not getting a mammogram in the United States today”
Makary: Breast ultrasound detects 90% to 95% of lesions mammograms catch
“It picks up 90 to 95% of the lesions that a mammogram would pick up.”
Makary predicts GLP-1 drug starter pricing will drop to $149
“With the GLP-I example, for example, it's gonna come down to a 149 dollars for the first three months.”
FDA reduces biosimilar approval timeline from up to 8 years to 2.5
“We have changed the requirements so that we use the same principles we use for small molecules If you are structurally the same as a small molecule branded drug, we're going to approve you with some other stipulations. And so we are reducing the cost of R&D of…”
Makary: 60% of US antibiotic prescriptions are unnecessary
“60% of antibiotics prescribed in the United States Are unnecessary.”
FDA changing regulations to close drug broadcast ad risk loophole
“We're closing that loop. We're changing the regulation to close that loop.”
Makary: FDA sent zero drug ad enforcement letters in previous year
“The Biden folks in the year before I came to the FDA sent out zero enforcement letters. A department of about 35 people in charge of sending out enforcement letters sent out zero enforcement letters.”
FDA issues 1,500 drug ad enforcement letters under Makary
“I sent out 1500 enforcement letters, including over a hundred cease and desist letters for ads that were creating a misleading impression, including online pharmacies that are advertising drugs without the same, ah side effects that pharma companies list when …”
Makary: FDA deregulating health wearables unless claiming medical-grade accuracy
“They're going to be deregulated, so you can give those results of any physiologic parameter, but if you say that it's a quote unquote medical grade blood pressure, then we are going to want to see the data to make sure that it's validated with the gold standar…”
Makary: U.S. food supply contains over 1,000 chemicals banned elsewhere
“So we have basically said we have a thousand chemicals plus in the U.S. Food supply that do, are not allowed in other food system supplies.”
Makary calls out Froot Loops for using petroleum dyes in U.S.
“Fruit Loops was making cereal for Canada, where the petroleum-based dyes were banned, and a different Fruit Loops for the United States for American kids.”
FDA initiates regulatory process to close GRAS food chemical loophole
“And so we've said, we have to close the loophole on grass. We started the regulatory process to do that.”
Makary: One in 12 boys in California is now diagnosed with autism
“One in 12 boys in California now being diagnosed with autism.”
Makary: 90% of body's serotonin is made in the gut
“90% of your body's serotonin, which is involved in mood, is made by your gut.”
Makary: Average two-year-old has received over 2.5 antibiotic courses
“The average two-year-old has already received over 2.5 courses of antibiotics.”
Makary: Researchers suppressed 1960s Minnesota study showing low-fat diets increased heart attacks
“The Minnesota heart study was supposed to be the end all randomized trial in the 19 sixties. It showed the opposite of what they thought. The low fat diet group. This, these are 9000 Minnesotans randomized. Low fat group had more heart attacks, not less. They …”